NanoSonic signs Trappsol Cyclo manufacturing agreement with Biologix
NanoSonic Products, a wholly owned subsidiary of CTD Holdings, has signed a manufacturing agreement with Florida Biologix for the production of the sterile liquid form of its Trappsol Cyclo product.
Trappsol Cyclo product is an orphan drug-designated treatment for Niemann Pick Type-C disease, also known as Childhood Alzheimer's.
The product is currently being administered in the US under a compassionate use IND, the company said.
NanoSonic Products president and CEO Jeffrey Tate said manufacturing of the liquid form of their Trappsol Cyclo is the first step in their stability testing project for this product.
"Obtaining stability data for this form of our product is a top priority, and the opportunity to work with Florida Biologix's manufacturing experts will move it forward quickly," Tate added.
CommentsPost a comment
Comments may be moderated for spam, obscenities or defamation.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs